FDA Approval Activities for this Drug… Exelon (rivastigmine tartrate) Capsules, 1.5 mg, 3 mg, 4.5 mg, & 6 mg., Novartis NDA 20-823/S3 01/05/01 05/09/03 Exelon (rivastigmine tartrate) Capsules, 1.5 mg, 3 mg, 4.5 mg, & 6 mg., Novartis NDA 20-823 4/21/00 8/16/01 4/24/00 10/11/01 Exelon Indication: is indicated for the treatment of mild to moderate dementia of the Alzheimer's type Exelon (rivastigmine tartrate) Solution, 2 mg/mL, Novartis NDA 21-025 4/21/00 4/24/00 4/24/00 4/11/02 Exelon Indication: is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Exelon (RIVASTIGMINE), Novartis Pharmaceuticals | Exelon (rivastigmine) capsules, Novartis Pharma, Labeling Revision | Exelon (rivastigmine) oral solution, Novartis Pharma, Labeling Revision Back to this API's Main Page.

Browse other API's patent/exclusivity pages… A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Find API by Brand Name | Industry Information | Prescription Drug Websites | Search | Site Map         © 2009 Betterchem.com